Skip Navigation LinksHome > March 2014 - Volume 22 - Issue 2 > Daptomycin Prevention of Vancomycin-Resistant Enterococcus B...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e31829ff3b0
Original Articles

Daptomycin Prevention of Vancomycin-Resistant Enterococcus Bacteremia in Colonized Patients With Acute Myelogenous Leukemia

Levitt, Laura A. MD*; Yacoub, Abraham T. MD; Khwaja, Sara I. MD, MS; Vincent, Albert L. PhD; Sandin, Ramon L. MD, MS, FCAP§; Greene, John N. MD, FACP

Collapse Box

Abstract

Abstract: Vancomycin-resistant enterococci (VRE) are a significant cause of bloodstream infections (BSIs) and mortality in patients with acute myelogenous leukemia undergoing chemotherapy or allogeneic hematopoietic stem cell transplant (HSCT). Fecal colonization with VRE is a major risk factor for development of VRE BSIs in neutropenic patients with a hematologic malignancy. Mucosal damage and neutropenia from high-dose chemotherapeutic agents allow enteric VRE to enter the systemic circulation via translocation resulting in a BSI. Recent studies have shown that 13.4% of VRE-colonized cancer patients and 34.2% of VRE-colonized patients who underwent allogeneic hematopoietic stem cell transplant developed VRE BSI, and a large percentage of these patients die from this infection. Here, we show that empiric or prophylactic treatment with daptomycin significantly reduces the percentage of VRE-colonized patients with acute myelogenous leukemia who will go on to develop BSIs after immunosuppressive treatment. In addition, we found a significant reduction in mortality caused by VRE BSIs in this patient population.

© 2014 by Lippincott Williams & Wilkins.

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.